Skip to Main Content

Scientific Session I: Tumor

Monday, April 30 | 2:00 pm - 5:30 pm | 394-396; Ernest N. Morial

Moderator(s): Randy Lynn Jensen, MD, PhD, FAANS; Pamela Stuart Jones, MD, MPH

Add to Calendar Monday, April 30 Monday, April 30 America/Chicago Scientific Session I: Tumor 394-396; Ernest N. Morial

2:00 pm - 2:04 pm

Introduction of the Ronald L. Bittner Lecture

4/30/2018 2:00:00 PM 4/30/2018 2:04:00 PM Introduction of the Ronald L. Bittner Lecture 394-396; Ernest N. Morial

2:05 pm - 2:39 pm

Ronald L. Bittner Lecture: Historical and Future Perspectives in Brain Tumor Therapy - Through the Surgeon’s and Patient’s Eyes

4/30/2018 2:05:00 PM 4/30/2018 2:39:00 PM Ronald L. Bittner Lecture: Historical and Future Perspectives in Brain Tumor Therapy - Through the Surgeon’s and Patient’s Eyes 394-396; Ernest N. Morial



Mark L. Rosenblum, MD, FAANS(L), is currently chairman emeritus of the department of neurosurgery in the Henry Ford Health System (HFHS). He has received many awards for his research and clinical work, including the first Charles B. Wilson Award from the AANS and CNS for life-long contributions to neuro-oncology. He has published seven books, 240 articles and chapters, trained 63 neurosurgeons and raised $45 million in philanthropy for neuroscience.

Dr. Rosenblum has served on several hospital and industry boards. He is presently the chief medical advisor for a healthcare process improvement company, is a consultant for Navigant and is an adjunct professor in the department of health management and policy in the School of Public Health at the University of Michigan. He has particular interest in the value of integrated specialty care, including the development of centers and institutes, and developing innovative delivery processes “through the eyes of the patient.”

2:40 pm - 2:49 pm

504. Five-aminolevulinic acid (5ALA) for fluorescence-guided surgery of high-grade gliomas (HGG): U.S. experience interim analysis.

4/30/2018 2:40:00 PM 4/30/2018 2:49:00 PM 504. Five-aminolevulinic acid (5ALA) for fluorescence-guided surgery of high-grade gliomas (HGG): U.S. experience interim analysis. 394-396; Ernest N. Morial

2:50 pm - 2:59 pm

505. Systemic and Local Immunosuppression In Patients With High-Grade Meningiomas

4/30/2018 2:50:00 PM 4/30/2018 2:59:00 PM 505. Systemic and Local Immunosuppression In Patients With High-Grade Meningiomas 394-396; Ernest N. Morial

3:00 pm - 3:09 pm

506. Genotype Based Local Targeted Therapy for Glioma

4/30/2018 3:00:00 PM 4/30/2018 3:09:00 PM 506. Genotype Based Local Targeted Therapy for Glioma 394-396; Ernest N. Morial

3:10 pm - 3:19 pm

507. Analysis of Mutational Processes in 23 Adult Hemispheric Diffuse Gliomas Identifies DNA-Damage Repair Deficiency as a Major Contributor to Gliomagenesis.

4/30/2018 3:10:00 PM 4/30/2018 3:19:00 PM 507. Analysis of Mutational Processes in 23 Adult Hemispheric Diffuse Gliomas Identifies DNA-Damage Repair Deficiency as a Major Contributor to Gliomagenesis. 394-396; Ernest N. Morial

3:20 pm - 3:29 pm

508. Convolutional Neural Networks Provide Rapid Intraoperative Diagnosis Of Neurosurgical Specimens Imaged With Stimulated Raman Histology

4/30/2018 3:20:00 PM 4/30/2018 3:29:00 PM 508. Convolutional Neural Networks Provide Rapid Intraoperative Diagnosis Of Neurosurgical Specimens Imaged With Stimulated Raman Histology 394-396; Ernest N. Morial

3:30 pm - 4:00 pm

Beverage Break in the AANS Exhibit Hall and Learning Center

4/30/2018 3:30:00 PM 4/30/2018 4:00:00 PM Beverage Break in the AANS Exhibit Hall and Learning Center 394-396; Ernest N. Morial

4:01 pm - 4:10 pm

509. Whole Exome and Targeted Sequencing of Adult Infiltrating Astrocytomas: Experience at a Single Institution.

4/30/2018 4:01:00 PM 4/30/2018 4:10:00 PM 509. Whole Exome and Targeted Sequencing of Adult Infiltrating Astrocytomas: Experience at a Single Institution. 394-396; Ernest N. Morial

4:11 pm - 4:20 pm

510. The Risk of Malignancy after Stereotactic Radiosurgery

4/30/2018 4:11:00 PM 4/30/2018 4:20:00 PM 510. The Risk of Malignancy after Stereotactic Radiosurgery 394-396; Ernest N. Morial

4:21 pm - 4:30 pm

511. CRISPR Improved: Inducible CRISPR-Interference Achieves Specific and Reversible PIKE-A Silencing in Glioblastoma

4/30/2018 4:21:00 PM 4/30/2018 4:30:00 PM 511. CRISPR Improved: Inducible CRISPR-Interference Achieves Specific and Reversible PIKE-A Silencing in Glioblastoma 394-396; Ernest N. Morial

4:31 pm - 4:40 pm

512. RNA Deconvolution Reveals Distinctive Immunogenetic Landscapes in Nf2 and non-Nf2 Meningiomas

4/30/2018 4:31:00 PM 4/30/2018 4:40:00 PM 512. RNA Deconvolution Reveals Distinctive Immunogenetic Landscapes in Nf2 and non-Nf2 Meningiomas 394-396; Ernest N. Morial

4:41 pm - 4:50 pm

513. Glioma Stem Cells Driven by Distinct BMI-1 and EZH2 Transcriptional Pathways Targeted Separately or Synergistically

4/30/2018 4:41:00 PM 4/30/2018 4:50:00 PM 513. Glioma Stem Cells Driven by Distinct BMI-1 and EZH2 Transcriptional Pathways Targeted Separately or Synergistically 394-396; Ernest N. Morial

4:51 pm - 5:00 pm

514. Multi-agent vs. Single-agent Intraventricular Chemotherapy for Patients with Neoplastic Meningitis (NM): Changing the Reputation of a Fearsome Disease

4/30/2018 4:51:00 PM 4/30/2018 5:00:00 PM 514. Multi-agent vs. Single-agent Intraventricular Chemotherapy for Patients with Neoplastic Meningitis (NM): Changing the Reputation of a Fearsome Disease 394-396; Ernest N. Morial

5:01 pm - 5:10 pm

515. Integrative Analysis Implicates MYC and MAX in Functional Pituitary Adenomas

4/30/2018 5:01:00 PM 4/30/2018 5:10:00 PM 515. Integrative Analysis Implicates MYC and MAX in Functional Pituitary Adenomas 394-396; Ernest N. Morial

5:11 pm - 5:20 pm

Whole-Sellar Stereotactic Radiosurgery for Cushing’s Disease: Results from a Multicenter, International Cohort Study

4/30/2018 5:11:00 PM 4/30/2018 5:20:00 PM Whole-Sellar Stereotactic Radiosurgery for Cushing’s Disease: Results from a Multicenter, International Cohort Study 394-396; Ernest N. Morial

5:21 pm - 5:30 pm

Glioblastoma comprises of two molecularly distinct immunological signatures

4/30/2018 5:21:00 PM 4/30/2018 5:30:00 PM Glioblastoma comprises of two molecularly distinct immunological signatures 394-396; Ernest N. Morial